Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema

Hereditary angioedema (HAE) is a group of rare, potentially life-threatening, and frequently debilitating diseases characterized by recurrent, and often with an unpredictable onset, of swelling attacks. HAE is heterogeneous, with considerable differences between its subtypes, patients, and even with...

Full description

Bibliographic Details
Main Authors: Anette Bygum, Paula Busse, Teresa Caballero, Marcus Maurer
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Medicine
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fmed.2017.00212/full
id doaj-58705acc28334df988a1370a48ba3166
record_format Article
spelling doaj-58705acc28334df988a1370a48ba31662020-11-24T23:21:39ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2017-12-01410.3389/fmed.2017.00212301257Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary AngioedemaAnette Bygum0Paula Busse1Teresa Caballero2Marcus Maurer3HAE Centre Denmark, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, DenmarkIcahn School of Medicine at Mount Sinai, New York, NY, United StatesAllergy Department, Hospital La Paz Institute for Health Research (IdiPaz), CIBERER U754, Madrid, SpainDepartment of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyHereditary angioedema (HAE) is a group of rare, potentially life-threatening, and frequently debilitating diseases characterized by recurrent, and often with an unpredictable onset, of swelling attacks. HAE is heterogeneous, with considerable differences between its subtypes, patients, and even within the same patient over time. During the past few years, several new on demand and prophylactic therapies have become available for HAE, allowing for individualized treatment. Therefore, to optimize HAE management, it is important to determine in all patients, the severity of their attacks, their disease activity, its therapeutic control, and its impact on their quality of life. In this manuscript, we review the existing tools to assess these aspects of HAE management, many of which are patient-reported outcome instruments. Also, we outline the current gaps of knowledge and what tools are still missing to allow for a comprehensive assessment of all patients with HAE including children.http://journal.frontiersin.org/article/10.3389/fmed.2017.00212/fullhereditary angioedemaseverityactivityimpactburdenquality of life
collection DOAJ
language English
format Article
sources DOAJ
author Anette Bygum
Paula Busse
Teresa Caballero
Marcus Maurer
spellingShingle Anette Bygum
Paula Busse
Teresa Caballero
Marcus Maurer
Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
Frontiers in Medicine
hereditary angioedema
severity
activity
impact
burden
quality of life
author_facet Anette Bygum
Paula Busse
Teresa Caballero
Marcus Maurer
author_sort Anette Bygum
title Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
title_short Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
title_full Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
title_fullStr Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
title_full_unstemmed Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
title_sort disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2017-12-01
description Hereditary angioedema (HAE) is a group of rare, potentially life-threatening, and frequently debilitating diseases characterized by recurrent, and often with an unpredictable onset, of swelling attacks. HAE is heterogeneous, with considerable differences between its subtypes, patients, and even within the same patient over time. During the past few years, several new on demand and prophylactic therapies have become available for HAE, allowing for individualized treatment. Therefore, to optimize HAE management, it is important to determine in all patients, the severity of their attacks, their disease activity, its therapeutic control, and its impact on their quality of life. In this manuscript, we review the existing tools to assess these aspects of HAE management, many of which are patient-reported outcome instruments. Also, we outline the current gaps of knowledge and what tools are still missing to allow for a comprehensive assessment of all patients with HAE including children.
topic hereditary angioedema
severity
activity
impact
burden
quality of life
url http://journal.frontiersin.org/article/10.3389/fmed.2017.00212/full
work_keys_str_mv AT anettebygum diseaseseverityactivityimpactandcontrolandhowtoassesstheminpatientswithhereditaryangioedema
AT paulabusse diseaseseverityactivityimpactandcontrolandhowtoassesstheminpatientswithhereditaryangioedema
AT teresacaballero diseaseseverityactivityimpactandcontrolandhowtoassesstheminpatientswithhereditaryangioedema
AT marcusmaurer diseaseseverityactivityimpactandcontrolandhowtoassesstheminpatientswithhereditaryangioedema
_version_ 1725570808065032192